A Temple-led research team headed by Walter J. Koch, PhD, the William Wikoff Smith Endowed Chair in Cardiovascular Medicine at the Lewis Katz School of Medicine at Temple University (LKSOM), Professor and Chair of Pharmacology at LKSOM, and Professor and Director of the Center for Translational Medicine at LKSOM, showed for the first time that blocking G protein-coupled receptor kinase 2 (GRK2) localization to mitochondria protects heart cells from ischemic injury and death, casting new light on GRK2 as a potential therapeutic target in post-injury heart failure. Dr. Koch was the senior investigator on the report, and the findings were published online in the journal Science Signaling. Medical Xpress provided coverage.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH